Individualizing SGLT2 inhibitors cardiovascular benefit in patients with type 2 diabetes: target trial emulation meets machine learning
As a reflection of advancements in prevention, intervention, and control strategies, the overall age-standardised burden of modifiable cardiovascular disease (CVD) risk factors is projected to
Authors
- Yosef Manla (ORCID: https://orcid.org/0000-0003-3096-1067)
- Wael Almahmeed (ORCID: https://orcid.org/0000-0003-0312-9910)
- Francesco Cosentino (ORCID: https://orcid.org/0000-0002-6967-5685)
Institutions
- Eisenhower Medical Center (US)
- Karolinska University Hospital (SE)
- Abu Dhabi Health Services (AE)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2025-09-28
- DOI
- https://doi.org/10.1093/eurjpc/zwaf625
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00